



# Financial Tear Sheet

## Corporate Profile

Codexis, Inc. (Nasdaq: CDXS), is a leading developer of biocatalysts for the pharmaceutical and fine chemical industries. Codexis utilizes its proprietary CodeEvolver® directed evolution technology platform and CodeXporter® enzyme production platform, for the discovery, identification, optimization, and efficient production of enzymes for its customers. Customers include global leaders such as Merck, Pfizer and Teva. For more information, see [www.codexis.com](http://www.codexis.com)

## Stock Performance

CDXS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$5.05
Change (%)	▼ 0.15 (2.88%)
Volume	87,750
52 Week Low	\$3.60
Market Cap	\$243,258,111
Rolling EPS	-0.22
PE Ratio	N/A
Shares Outstanding	48,169,923

Data as of 06/27/17 4:00 p.m. ET



## Recent News Releases

May 30, 2017

[Codexis to Present at Two Upcoming Investment Conferences](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

	Filing Date	Form
May 09, 2017 <a href="#">Codexis Reports Financial Results for the First Quarter of 2017</a>	06/16/17	4
	06/16/17	4
May 02, 2017 <a href="#">Codexis to Hold 2017 First Quarter Conference Call on May 9</a>	06/16/17	4
	06/16/17	4

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed